

Centrosome aberrations and G₁ phase arrest after *in vitro* and *in vivo* treatment with the SRC/ABL inhibitor dasatinib

Alice Fabarius,¹ Michelle Giehl,¹ Blanka Rebacz,² Alwin Krämer,² Oliver Frank,¹ Claudia Haferlach,³ Peter Duesberg,¹ Rüdiger Hehlmann,¹ Wolfgang Seifarth,¹ and Andreas Hochhaus¹

¹III. Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim; ²Clinical Cooperation Unit Molekulare Hämatologie/Onkologie, DKFZ and Department of Internal Medicine V, Universität Heidelberg, Heidelberg; ³MLL Münchner Leukämielabor GmbH, München, Germany

Citation: Fabarius A, Giehl M, Rebacz B, Krämer A, Frank O, Haferlach C, Duesberg P, Hehlmann R, Seifarth W, and Hochhaus A. Centrosome aberrations and G₁ phase arrest after *in vitro* and *in vivo* treatment with the SRC/ABL inhibitor dasatinib. *Haematologica* 2008 doi: 10.3324/haematol.12793

Supplementary Table S1. Cell proliferation and standard deviation of NHDF after treatment with dasatinib, imatinib, nilotinib, INNO-406 or PP2 at different concentrations and for different periods of incubation.

NHDF-cultures	Concentration	Cell proliferation (10 ⁵) and standard deviation after			
		24 hours	48 hours	72 hours	
+ Dasatinib	Control (Fig 1A)	3.5 ± 0.3	7.06 ± 0.3	10.16 ± 0.3	
	Control (Fig 1B)	11.3 ± 2	12.9 ± 1.5	15 ± 2.2	
	1nM	3.9 ± 0.1	3 ± 0.2	6.8 ± 0.8	
	10nM	4.7 ± 0.3	6.1 ± 1.1	7.3 ± 0.1	
	25nM	3.2 ± 0	6.7 ± 0.9	7.3 ± 1.9	
	50nM	4.9 ± 0.3	5.3 ± 0.1	5.6 ± 1.2	
	100nM	3.5 ± 0.1	4.9 ± 0.1	5.7 ± 0.1	
	250nM	3.6 ± 0.6	5.8 ± 2.2	4.8 ± 0.8	
	500nM	7.53 ± 0.5	9.33 ± 1.2	9.06 ± 1.1	
	1µM	9.6 ± 1	9.6 ± 1	8.46 ± 1.1	
	2µM	8.86 ± 1	8.13 ± 0.4	6.26 ± 1.4	
	+ Imatinib	Control	10.06 ± 1	9.73 ± 0.3	11.86 ± 1.6
		500nM	9.13 ± 1	7.8 ± 1.5	9.3 ± 3.6
1µM		7.73 ± 1.8	7.6 ± 0.8	8.8 ± 2	
2µM		3.5 ± 0.9	6.7 ± 0.5	7.3 ± 1.3	
5µM		3.8 ± 1.3	6.5 ± 1.1	6.4 ± 0.9	
+ Nilotinib	Control	4.46 ± 1.3	6.13 ± 0.2	9.86 ± 1.5	
	500nM	3.6 ± 0.6	7.2 ± 1.5	10.4 ± 1.8	
	1µM	3.2 ± 0.4	6.93 ± 0.6	9.46 ± 0.4	
	2µM	3.66 ± 0.5	6.13 ± 0.8	11.33 ± 2.4	
+ INNO-406	Control	3.5 ± 0.6	7.06 ± 0.4	10.02 ± 2	
	100nM	4.5 ± 1.5	-	10.73 ± 1.6	
	500nM	4.5 ± 1	7.4 ± 0.3	7.33 ± 2.7	
	1µM	5.06 ± 0.9	5.53 ± 1.5	4.33 ± 1.3	
+ PP2	Control	2.33 ± 0.9	6.06 ± 2.1	6.4 ± 2.6	
	100nM	3.6 ± 0.6	8.73 ± 0.4	12.7 ± 1.5	
	100nM	3.7 ± 1.3	10.1 ± 1.6	12.3 ± 2.7	
	500nM	4.4 ± 0.9	6.4 ± 0.3	8.47 ± 0.1	
	1µM	3.3 ± 1.2	8.4 ± 1.6	7.93 ± 1.4	
	2µM	2.1 ± 0.2	6.8 ± 1	7.4 ± 1.4	